Status:
COMPLETED
Recurrence Risk Evaluation by 21-gene Detection
Lead Sponsor:
Xijing Hospital
Conditions:
Relationship and Consistency Analysis
Eligibility:
FEMALE
18-70 years
Brief Summary
Breast cancer patients with early breast cancer were enrolled according to the inclusion criteria. Baseline characteristics were recorded from medical record system. Recurrence score were obtained by ...
Eligibility Criteria
Inclusion
- breast cancer in stage I-III, tumor size\>0.5cm
- lymph nodes negative
- hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+）
- HER2 negative（IHC 0 or +， FISH negative）
- receive endocrine therapy only
- enough FFPE samples within 10 years（3\~6 10μm ）
- patients with integrated medical records
Exclusion
- Tumor cells \<5%
- Isolated RNA\<500ng
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT03841266
Start Date
January 1 2019
End Date
February 1 2019
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing hoapital
Xi'an, China, 710032